Deals Of The Week: Shire/Heptares, NicOx/Altacor, UCB/Oxford University

 
• By Michael Goodman, Paul Bonanos, John Davis, and Wendy Diller

This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.

More from Europe

More from Geography